Does accumulation of advanced glycation end products contribute to the aging phenotype?

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 65 A, Issue 9, 2010, Pages 963-975

  Semba, Richard D ^a   Nicklett, Emily J ^b   Ferrucci, Luigi ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Advanced glycation end products; Aging; Diabetes; Diet; Inflammation; Longevity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ALAGEBRIUM; AMINOGUANIDINE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; THIAZOLE DERIVATIVE;

AGING; BONE; BRAIN; DIET; DRUG ANTAGONISM; ERYTHROCYTE; EYE; FOOD ANALYSIS; HEART MUSCLE; HUMAN; INFLAMMATION; KIDNEY; LIVER; LONGEVITY; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; REVIEW; SKELETAL MUSCLE; TENDON;

AGING; BONE AND BONES; BRAIN; DIET; ENZYME INHIBITORS; ERYTHROCYTES; EYE; FOOD ANALYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HUMANS; INFLAMMATION; KIDNEY; LIVER; LONGEVITY; MUSCLE, SKELETAL; MYOCARDIUM; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; TENDONS; THIAZOLES;

EID: 77955867860     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glq074     Document Type: Article

References (109)

1. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clin Interv Aging. 2007;2:401-412.
2. Cho SJ, Roman G, Yeboah F, Konishi Y. The road to advanced glyca-tion end products: A mechanistic perspective. Curr Med Chem. 2007; 14:1653-1671.
3. Maillard LC. Action des acides aminés sur les sucres: formation des mélanoïdines par voie méthodique. C R Acad Sci. 1912;154:66-68.
4. Trivelli LA, Tanney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med. 1971;284:353-357.
5. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1-21.
6. Bunn HF, Gabby KH, Gallop PM. The glycosylation of hemoglobin: Relevance to diabetes mellitus. Science. 1978;200:21-27.
7. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005; 83:876-886.
8. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
9. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci\USA. 1992;89:12043-12047.
10. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci\USA. 1997; 94:6474-6479.
11. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum car-boxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74-79.
12. Semba RD, Ferrucci L, Fink JC, et al. Elevated serum advanced gly-cation end products and their circulating receptors are associated with renal insuffciency in a cohort of older community-dwelling women. Am J Kidney Dis. 2009;53:51-58.
13. Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Elevated serum advanced glycation end products are associated with renal insuf-fciency: The Baltimore Longitudinal Study of Aging. J Ren Nutr. 2010;20:74-81.
14. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr. 2009;48:38-44.
15. Semba RD, Patel KV, Sun K, et al. Association of serum carboxym-ethyl-lysine, a dominant advanced glycation end product, with anemia in adults: The Baltimore Longitudinal Study of Aging. J Am Geriatr Soc. 2008;56:2145-2147.
16. Semba RD, Ferrucci L, Sun K, Patel K, Guralnik JM, Fried LP. Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women. Age Ageing. 2009;38:283-289.
17. Dalal M, Ferrucci L, Sun K, Beck J, Fried LP, Semba RD. Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. J Gerontol A Biol Sci Med Sci. 2009;64:132-137.
18. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: The InCHIANTI study. Eur J Appl Physiol. 2010;108:191-195.
19. Semba RD, Ferrucci L, Sun K, et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res. 2009;21:182-190.
20. Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, and advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc. 2009;57:1874-1880.
21. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glyca-tion end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci\USA. 1994;91:8807-8811.
22. Glenn JV, Mahaff H, Wu K, et al. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci. 2009;50:441-451.
23. Monnier VM, Mustata GT, Biemel KL, et al. Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: An update on "a puzzle nearing resolution." Ann N Y Acad Sci. 2005; 1043:533-544.
24. Greenwald SE. Ageing of the conduit arteries. J Pathol. 2007; 211:157-172.
25. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9-21.
26. e-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740-31749.
27. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor kappa-B. Diabetes. 2001;50:2792-2808.
28. e-(carboxymethyl)lysine in foods and related systems. Ann N Y Acad Sci. 2008;1126:20-24.
29. e-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography-mass spectrometry. Amino Acids. 2009;36: 317-326.
30. e-carboxymethyllysine by a reserved-phase high-performance liquid chromatography method. J Chromatogr. 1994;672:242-246.
31. Delgado-Andrade C, Rufán-Henares JA, Morales FJ. Study on fuo-rescence of Maillard reaction compounds in breakfast cereals. Mol Nutr Food Res. 2006;50:799-804.
32. Yaacoub R, Saliba R, Nsouli B, Khalaf G, Birlouez-Aragon I. Formation of lipid oxidation and isomerization products during processing of nuts and sesame seeds. J Agric Food Chem. 2008;56:7082-7090.
33. e-carboxy-methyllysine in milk products by a modifed reversed-phase HPLC method. Food Chem. 1999;65:547-553.
34. Chao PC, Hsu CC, Yin MC. Analysis of glycative products in sauces and sauce-treated foods. Food Chem. 2009;113:262-266.
35. Tan D, Yang Y, Lo CY, Sang S, Ho CT. Methylglyoxal: Its presence in beverages and potential scavengers. Ann N Y Acad Sci. 2008; 1126:72-75.
36. Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babael-Jadidi R, Thornalley PJ. Assay of advanced glycation endproducts in selected beverages and food by liquid chromatog-raphy with tandem mass spectrometric detection. Mol Nutr Food Res. 2005;49:691-699.
37. Birlouez-Aragon I, Pischetsrieder M, Leclère J, et al. Assessment of protein glycation markers in infant formulas. Food Chem. 2004; 87:253-259.
38. e-(carboxymethyl)lysine in breast milk-and formula-fed infants. Ann N Y Acad Sci. 2008;1126:177-180.
39. Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S. Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett. 1996;208:53-56. (Pubitemid 26128106)
40. e-(carboxymethyl) ly-sine and hexitol-lysine. Free Radic Biol Med. 2001;31:175-180.
41. Southern L, Williams J, Esiri MM. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: Relation to vascular dementia. BMC Neurol. 2007;7:35.
42. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests a pathological synergism of Alzheimer's disease and diabetes mellitus. Neuro-biol Dis. 2010;37:67-76.
43. Kumar PA, Kumar MS, Reddy GB. Effect of glycation on a-crystallin structure and chaperone-like function. Biochem J. 2007;408:251-258.
44. Franke S, Dawczynski J, Strobel J, Niwa T, Stahl P, Stein G. Increased levels of advanced glycation end products in human cata-ractous lenses. J Cataract Refract Surg. 2003;29:998-1004.
45. Gul A, Rahman MA, Salim A, Simjee SU. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J Diabetes Complications. 2009;23:343-348.
46. e(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:1855-1859.
47. Ni J, Yuan X, Gu J, et al. Plasma protein pentosidine and carboxym-ethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics. 2009;8:1921-1933.
48. Basta G, Schmidt AM, de Caterina R. Advanced glycation end products and vascular infammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582-592. (Pubitemid 39078671)
49. e-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis. 1999;144:41-47.
50. Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glyca-tion end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating age proteins. Proc Natl Acad Sci\USA. 1994;91:8807-8811.
51. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxi-dant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269:9889-9897.
52. Simm A, Casselmann C, Schubert A, Hofmann S, Reimann A, Silber RE. Age associated changes of AGE-receptor expression: RAGE up-regulation is associated with human heart dysfunction. Exp Geron-tol. 2004;39:407-413.
53. van Heerebeek L, Hamdani N, Handoko L, et al. Diastolic stiffness of the failing diabetic heart. Importance of fbrosis, advanced glyca-tion end products, and myocyte resting tension. Circulation. 2008;117:43-51.
54. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000;37:87-92.
55. Miura J, Yamagishi SI, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabet Complications. 2003;17:16-21.
56. Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CDA. Advanced glycation end products are associated with pulse pressure in type 1 diabetes. The EURODIAB prospective complications study. Hypertension. 2005;46:232-237.
57. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glyca-tion end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 1999;22: 1186-1190.
58. Steine K, Larsen JR, Stugaard M, Berg TJ, Brekke M, Dahl-Jørgensen K. LV systolic impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts. Eur J Heart Fail. 2007;9:1044-1050.
59. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H. Increased serum concentrations of advanced glycation end products: A marker of coronary artery disease activity in type 2 diabetic patients. Heart. 2001;85:87-91.
60. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care. 2001;24:1620-1623.
61. McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens. 2007;20:242-247.
62. Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosi-dine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007;13:199-206.
63. Kilhovd BK, Juutilainen A, Lehto S, et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: A population-based 18 year follow-up study. Diabetologia. 2002;50:1409-1417.
64. Ando K, Beppu M, Kikugawa K, Nagai R, Horiuchi S. Membrane proteins of human erythrocytes are modifed by advanced glycation end products during aging in the circulation. Biochem Biophys Res Commun. 1999;258:123-127.
65. Iwata H, Ukeda H, Maruyama T, Fujino T, Sawamura M. Effect of carbonyl compounds on red blood cells deformability. Biochem Bio-phy Res Commun. 2004;321:700-706.
66. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specifc receptor inducing oxidant stress in the vas-culature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci\USA. 1994;91:7742-7746.
67. Thomas MC, Tsalamandris C, MacIsaac R, et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 2004;66:1167-1172.
68. Hyogo H, Yamagishi S. Advance glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des. 2008;14:969-972.
69. Schinzel R, Münch G, Heidland A, Sebekova K. Advanced glycation end products in end-stage renal disease and their removal. Nephron. 2001;87:295-303. (Pubitemid 32260829)
70. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocal-ization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implications for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest. 1997;100:2995-3004.
71. Oldfeld MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofbroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001;108:1853-1863.
72. Chuang P Y, Yu Q, Uribarri J, He JC. Advanced glycation endprod-ucts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 2007;72:965-1876
73. Makita Z, Radoff S, Rayfeld EJ, et al. Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836-842.
74. Stam F, Schalkwijk CG, van Guldener C, ter Wee PM, Stehouwer CDA. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of en-dothelial dysfunction and infammation in non-diabetic individuals. Nephrol Dial Transplant. 2006;21:677-682.
75. Hein GE. Glycation endproducts in osteoporosis\is there a pathophysiologic importance? Clin Chim Acta. 2006;371:32-36.
76. Odetti P, Rossi S, Monacelli F, et al. Advanced glycation end-products and bone loss during aging. Ann N Y Acad Sci. 2005;1043:710-717.
77. Tang S Y, Zeenath U, Vashishth D. Effects of non-enzymatic glyca-tion on cancellous bone fragility. Bone. 2007;40:1144-1151.
78. e-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology. 2003;42:1242-1246.
79. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1013-1019.
80. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:2380-2386.
81. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking and advanced glycation endproducts in aging human skeletal muscle. J Appl Physiol. 2007;103:2068-2076.
82. Snow LM, Fugere NA, Thompson LV. Advanced glycation end-product accumulation and associated protein modifcation in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci. 2007; 62:1204-1210.
83. Couppé C, Hansen P, Kongsgaard M, et al. Mechanical properties and collagen cross-linking of the patellar tendon in old and young men. J Appl Physiol. 2009;107:880-886.
84. Verzijl N, deGroot J, Ben Zaken C, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: A possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002;46:114-123.
85. Waters A, Heron K. No lunch left behind. New York Times. February 20, 2009.
86. Delgado-Andrade C, Seiquer I, Navarro MP, Morales FJ. Maillard reaction indicators in diets usually consumed by adolescent population. Mol Nutr Food Res. 2007;51:341-351.
87. Duffey KJ, Gordon-Larsen P, Steffen LM, Jacobs DR Jr., Popkin BM. Regular consumption from fast food establishments relative to other restaurants is differentially associated with metabolic outcomes in young adults. J Nutr. 2009;139:2113-2118.
88. McNaughton SA, Mishra GD, Brunner EJ. Dietary patterns, insulin resistance, and incidence of type 2 diabetes in the Whitehall II study. Diabetes Care. 2008;31:1343-1348.
89. Morgenstern LB, Escobar JD, Sánchez BN, et al. Fast food and neighborhood stroke risk. Ann Neurol. 2009;66:165-170.
90. Monsivais P, Drewnowski A. The rising cost of low-energy-dense foods. J Am Diet Assoc. 2007;107:2071-2076.
91. Block JP, Scribner RA, DeSalvo KB. Fast food, race/ethnicity, and income. A geographic analysis. Am J Prev Med. 2004;27:211-217.
92. Ballew C, White LL, Strauss KF, Benson LJ, Mendlein JM, Mokdad AH. Intake of nutrients and food sources of nutrients among the Na-vajo: fndings from the Navajo Health and Nutrition Survey. J Nutr. 1997;127:2085S-2093S.
93. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans. 2007;35:853-856.
94. Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl. 2007;106:S54-60.
95. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464-1470.
96. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, de-Groof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191-195.
97. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24:32-40.
98. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxam-ine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605-614.
99. Henle T. AGEs in foods: do they play a role in uremia? Kidney Int. 2003;63(suppl 84):S145-S147.
100. Somoza V, Wenzel E, Weiss C, Clawin-Rädecker I, Grübel N, Erber-sdobler HF. Dose-dependent utilization of casein-linked lysinoala-nine, N (epsilon)-fructoselysine and N (epsilon)-carboxymethyllysine in rats. Mol Nutr Food Res. 2006;50:833-841.
101. Pischetsrieder M, ed. Special issue: Are dietary AGEs/ALEs a health risk? Mol Nutr Food Res. 2007;51:1069-1119.
102. Ames JM. Evidence against dietary advanced glycation endproducts being a risk to human health. Mol Nutr Food Res. 2007;51:1085-1090.
103. Scaron;ebeková K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects\PRO. Mol Nutr Food Res 2007, 51, 1079-1084.
104. Erbersdobler HF, Lohmann M, Buhl K. Utilization of early Maillard reaction products by humans. In: Friedman M, ed. Nutrition and toxicological consequences of food processing. New York: Plenum Press; 1991:363-370.
105. Erbersdobler HF, Faist V. Metabolic transit of Amadori products. Nahrung. 2001;45:177-181.
106. Förster A, Kühne Y, Henle T. Studies on absorption and elimination of dietary Maillard reaction products. Ann N Y Acad Sci. 2005;1043: 474-481.
107. Negrean M, Stirban A, Stratmann B, et al. Effects of low-and high-advanced glycation endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85:1236-1243.
108. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30:2579-2582.
109. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al. A diet based on high-heat\treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr. 2010;91: 1220-1226.